FDXACB1
Ferredoxin-fold anticodon-binding domain-containing protein 1
Also known as: FDXA1_HUMAN, hCG_2033039, LOC91893
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- Q9BRP7
- Gene
- FDXACB1
- Ensembl
- ENSG00000255561
- Chromosome
- 11
- Canonical length
- 624 aa
- Protein class
- Predicted intracellular proteins
- Subcellular location
- Nucleoplasm,Cytosol
OverviewNCBI Gene
This gene encodes a protein which contains a ferredoxin-fold anticodon-binding domain which is contained in a subset of phenylalanyl tRNA synthetases. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Aug 2011]
Canonical amino-acid sequenceUniProt
624 residues, UniProt reviewed canonical sequence.
>Q9BRP7|FDXACB1
1 MAPRRLLLVG EGNFSFAAAL SETLDQSTQL TATCLQRPAE LARDPLAWEN LQCLRERGID
61 VRFGVDCTQL ADVFELHERE FDQIYFIFPH CGRKAGVAKN RELLAKFFQS CADVLAEEGE
121 VHVALCRGQG GTPADKPQRE WHNSWQVVAM AALGGLILSD VYPFSCKAVA GYKCTGYRSQ
181 DKSFHVEGAL NHIFTRSLPF EGSQPRIFRI KLGNQWFSFP EPEALVGKLN RGFLEAPSCH
241 PIKTINEKLI AELGKVFPLK RLKCSYPLLP QEGTSVLPFW NCDFLSAAFW ISLHEDNSNS
301 ESLTGGTSQD VEDFLVSFSE LSLLKNPGRD GKEEACEGTC GQAKICLRPS LLVHVQDVIE
361 VPDFLSGSLH ILSGPVFQKC HILPFTMPAF HETLFILGVN QNLKDGCLQS LLDHLKGILD
421 SLLTQTLPES SKLSSLVKFV LQSNGKDYMI RVKTHNFSPD CTEDLIIGSV ITSATSVIHK
481 DQCFVFVSMN LDLLAMLVWC ISDWRMLWTF DNRFLKNFVP GKIEPFKSHS LYPPCYVHDV
541 SFWIDQKKGF DELEFHTVAR AVSQDTIISI QFLSRFQHPK TQQVSLCYRL TYQTCDKALT
601 QQQVASMQSQ FRKEIQQHLY VIPRLocalizationUniProt · AlphaFold · HPA
Whether an antibody against FDXACB1 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Intracellular
- Secreted
- No
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.28
- Highest tissue expression
- 3 nTPM
Expression across tissuesHPA
Tissue
- tonsil: 3 nTPM
- lymph node: 2.9 nTPM
- testis: 2.9 nTPM
- skin: 2.5 nTPM
- epididymis: 2.2 nTPM
- spleen: 2.2 nTPM
Single-cell type
- cardiomyocytes: 13 nCPM
- epicardial cells: 4.5 nCPM
- early spermatids: 1.9 nCPM
- adipocytes: 1.7 nCPM
- mucous neck cells: 0.4 nCPM
- other brain neurons: 0.4 nCPM
Immune cell
- naive CD8 T-cell: 7.5 nTPM
- naive CD4 T-cell: 6.5 nTPM
- MAIT T-cell: 6.4 nTPM
- gdT-cell: 4.9 nTPM
- NK-cell: 4.8 nTPM
- memory B-cell: 4.6 nTPM
Brain region
- hypothalamus: 2.8 nTPM
- basal ganglia: 2.4 nTPM
- spinal cord: 2.4 nTPM
- white matter: 2.4 nTPM
- hippocampal formation: 2.3 nTPM
- medulla oblongata: 2.3 nTPM
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 1.18
- gnomAD pLI
- 0
- gnomAD missense Z
- 0.07
- DepMap mean gene effect
- -0.01
- DepMap dependency class
- selective
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
Molecular functions
Cellular components
Protein domainsUniProt · Pfam · InterPro
- Ferrodoxin-fold anticodon-binding domain
- Ferrodoxin-fold anticodon-binding domain superfamily
- Class II Aminoacyl-tRNA synthetase/Biotinyl protein ligase (BPL) and lipoyl protein ligase (LPL)
- Ferredoxin-fold anticodon binding domain
- 25S rRNA (uridine-N(3))-methyltransferase BMT5-like
- rRNA (uridine-N3-)-methyltransferase BTM5-like
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads FDXACB1 as an antibody target. Whether an autoantibody or antibody against FDXACB1 could matter depends on whether native FDXACB1 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
FDXACB1 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.
Annotation status
The present source text does not explicitly label FDXACB1 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...